Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Acquired by Atria Investments Inc

Atria Investments Inc lifted its holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 70.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,684 shares of the biotechnology company’s stock after purchasing an additional 9,384 shares during the quarter. Atria Investments Inc’s holdings in Anavex Life Sciences were worth $244,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AVXL. Nwam LLC purchased a new position in shares of Anavex Life Sciences in the third quarter worth $5,172,000. Barclays PLC increased its position in shares of Anavex Life Sciences by 70.4% in the 3rd quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock valued at $882,000 after acquiring an additional 64,101 shares during the period. Geode Capital Management LLC raised its stake in Anavex Life Sciences by 2.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company’s stock worth $10,699,000 after acquiring an additional 51,946 shares during the last quarter. Atria Wealth Solutions Inc. acquired a new stake in Anavex Life Sciences during the 4th quarter worth about $291,000. Finally, Gladstone Institutional Advisory LLC purchased a new stake in Anavex Life Sciences during the 4th quarter valued at about $279,000. 31.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AVXL has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and issued a $42.00 price target on shares of Anavex Life Sciences in a report on Tuesday, February 18th. D. Boral Capital reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a report on Wednesday, February 12th.

Anavex Life Sciences Price Performance

Shares of NASDAQ:AVXL opened at $9.31 on Wednesday. The business’s 50 day moving average price is $9.20 and its 200-day moving average price is $8.09. Anavex Life Sciences Corp. has a 1 year low of $3.25 and a 1 year high of $14.44. The firm has a market capitalization of $791.95 million, a price-to-earnings ratio of -16.93 and a beta of 0.94.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.03. On average, sell-side analysts expect that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.